2. Friedman GD.  Screening criteria for drug monitoring:  the Kaiser-Permanente drug reaction monitoring system.  J Chronic Dis 1972;25:11-20.

3. Friedman GD, Collen MF.  A method of monitoring adverse drug reactions.  In:  LeCam L, Neyman J, Scott EL, eds. Proceedings of the Sixth Berkeley Symposium on Mathematical Statistics and Probability, vol VI.  Berkeley:  University of California Press, 1972:367-82.

4. Klatsky AL, Friedman GD, Siegelaub AB.  Alcohol consumption before myocardial infarction:  results from the Kaiser-Permanente epidemiologic study of myocardial infarction.  Ann Intern Med 1974;81:294-301.

5. Friedman GD, Klatsky AL, Siegelaub AB.  The leukocyte count as a predictor of myocardial infarction.  N Engl J Med 1974;290:1275-8. [Correction: 1974;291:1361]

6. Klatsky AL, Friedman GD, Siegelaub AB, Gerard MJ.  Alcohol consumption and blood pressure:  Kaiser-Permanente multiphasic health examination data.  N Engl J Med 1977;296:1194-200.

7. Friedman GD, Herrinton LJ.  Obesity and multiple myeloma.  Cancer Causes Control 1994;5:479-83.  

8. Friedman GD, Ury HK.  Initial screening for carcinogenicity of commonly used drugs.  J Natl Cancer Inst 1980;65:723-33.

9. Friedman GD, Ury HK.  Screening for possible drug carcinogenicity:  second report of findings.  J Natl Cancer Inst 1983;71:1165-75.

10. Selby JV, Friedman GD, Fireman BH.  Screening prescription drugs for possible carcinogenicity:  eleven to fifteen years of follow-up.  Cancer Res 1989;49:5736-47.

11. Van Den Eeden SK, Friedman GD.  Prescription drug screening for subsequent carcinogenicity.  Pharmacoepidemiol Drug Saf 1995;4:275-87.

12. Friedman GD.  Barbiturates and lung cancer in humans.  J Natl Cancer Inst 1981;67:291-5.

13. Friedman GD, Habel LA.  Barbiturates and lung cancer: a reevaluation.  Int J Epidemiol 1999;28:375-9.

14. Habel LA, Bull SA, Friedman GD.  Barbiturates, smoking and bladder cancer risk.  Cancer Epidemiol Biomarkers Prev 1998;7:1049‑50.

15. Friedman GD.  Re:  antidepressant drugs, depression, and cancer:  an editor comments.  Am J Epidemiol 1992;136:1415-6.

16. Habel LA, Levin TR, Friedman GD.  Cimetidine use and risk of breast, prostate, and other cancers.  Pharmacoepidemiol Drug Saf 2000;9:149-55.

17. Friedman GD.  Digitalis and breast cancer [Letter].  Lancet 1984;2:875.

18. Selby JV, Friedman GD.  Epidemiologic evidence of an association between body iron stores and risk for cancer.  Int J Cancer 1988;41:677-82.

19. Herrinton LJ, Friedman GD, Baer D, Selby JV.  Transferrin saturation and subsequent risk of cancer.  Am J Epidemiol 1995;142:692-8.

20. Friedman GD.  Lindane and cancer in humans:  a false alarm?  Pharmacoepidemiol Drug Saf 1997;6:129-34.

21. Herrinton LJ, Friedman GD. Methylergonovine maleate and risk of breast cancer [Letter].  Ann Epidemiol 1997;7:427-9.

22. Friedman GD.  Cancer after metronidazole [Letter].  N Engl J Med 1980;302:519.

23. Friedman GD, Selby JV.  Metronidazole and cancer [Letter].  JAMA 1989;261:866.

24. Friedman GD.  Phenylbutazone, musculoskeletal disease, and leukemia.  J Chronic Dis 1982;35:233-43.

25. Friedman GD.  Multiple myeloma: relation to propoxyphene and other drugs, radiation and occupation.  Int J Epidemiol 1986;15:424-6.

26. Friedman GD.  Rauwolfia and breast cancer:  no relation found in long-term users age fifty and over.  J Chronic Dis 1983;36:367-70.

27. Friedman GD, Coates AO, Potter JD, Slattery ML.  Drugs and colon cancer. Pharmacoepidemiol Drug Saf 1998;7:99-106.  

28. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans.(1980) Volume 24.  Some pharmaceutical drugs.   World Health Organization, International Agency for Research on Cancer.

29. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. (1987) Supplement No. 7: Overall evaluations of carcinogenicity: an updating of IARC Monographs Volumes 1-42.   World Health Organization, International Agency for Research on Cancer.

30. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. (1990) Volume 50: Pharmaceutical drugs.   World Health Organization, International Agency for Research on Cancer.

31. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. (1996) Volume 66: Some pharmaceutical drugs.   World Health Organization, International Agency for Research on Cancer.

32. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. (2000) Volume 76: Some antiviral and antineoplastic drugs and other pharmaceutical agents. World Health Organization, International Agency for Research on Cancer.

33. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. (2001) Volume 79: Some thyrotropic drugs.   World Health Organization, International Agency for Research on Cancer.

34. Oestreicher N, Friedman GD, Jiang S-F, Chan J, Quesenberry C, Habel LA. Methylphenidate use in children and risk of cancer at 17 sites: results of surveillance analyses.  Pharmacoepidemiol Drug Saf 2007; 16:1268-72.

35. Friedman, GD, Oestreicher N, Chan J, Quesenberry CP Jr, Udaltsova N, Habel LA. Antibiotics and risk of breast cancer: up to 9 years of follow-up of 2.1 million women.  Cancer Epidemiol Biomarkers Prev 2006; 15:2102-6.

36. Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA.  Screening statins for possible carcinogenic risk: up to nine years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008; 17:27-36. Erratum 17:751.

37. Friedman GD, Jiang S-F, Udaltsova N, Chan J, Habel LA. Pharmaceuticals that cause mammary gland tumors in animals: findings in women.  Breast Cancer Res Treat 2009; 116:187-94.

38. Friedman GD, Jiang S-F, Udaltsova N, Quesenberry CP Jr, Chan J, Habel, LA.  Epidemiologic evaluation of pharmaceuticals with limited evidence of carcinogenicity. Int J Cancer 2009; 125:2173-8.IARC

39. Friedman GD, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA. Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened.  Cancer Causes Control 2009; 20:1821-35.

40. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics.  Pharmacoepidemiol Drug Saf 2006; 15:291-303.

If you have any comments or questions, please send a message to super1@pitt.edu